Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Niral Patel

Pulmonary Disease San Diego, CA Medical Doctor

NPI 1841533221 CMS profile 4216899

200 W Arbor Dr, San Diego, CA 92103

Open in the dashboard

General payments

$48,000

142 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Niral Patel of San Diego, CA is reported in the CMS Open Payments database as having received $48,000 across 142 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $20,506 48
2024 General $2,135 28
2023 General $15,655 24
2022 General $361 5
2021 General $6,316 11
2020 General $749 5
2019 General $2,279 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Niral Patel
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Niral Patel were reported at $20,506. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Niral Patel Pulmonary Disease median Middle half National median
2019 $2,279 $377 $109–$1,340 $163
2020 $749 $230 $56–$907 $114
2021 $6,316 $269 $68–$1,072 $132
2022 $361 $390 $100–$1,457 $149
2023 $15,655 $419 $114–$1,659 $160
2024 $2,135 $476 $123–$1,818 $164
2025 $20,506 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $22,373 41 payments
  2. Olympus America Inc. $18,355 31 payments
  3. Pinnacle Biologics, Inc $2,336 19 payments
  4. Pulmonx Corporation $1,251 17 payments
  5. Boston Scientific Corporation $1,007 5 payments
  6. Steris Corporation $662 8 payments
  7. Olympus Corporation of the Americas $628 9 payments
  8. Olympus Medical Systems Corporation $440 2 payments
  9. ERBE USA Inc $354 3 payments
  10. Noah Medical Corporation $235 2 payments
  11. Other $359 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $21,705 12 payments
  2. Consulting Fee $10,265 10 payments
  3. Food and Beverage $6,022 94 payments
  4. Education $6,000 2 payments
  5. Travel and Lodging $4,008 24 payments
Products named General payments · program years 2019–2025
  1. Spiration Valve System $17,582 28 payments
  2. DA VINCI SP $14,500 6 payments
  3. Single-Use flexible Video Bronchoscope $6,920 8 payments
  4. Da Vinci Surgical System Surgery $4,873 34 payments
  5. Da Vinci Surgical System Surgery $3,000 1 payment
  6. Photofrin $2,336 19 payments
  7. CHARTIS CATHETER $1,067 15 payments
  8. ZEPHYR ENDOBRONCHIAL VALVE $1,067 15 payments
  9. PULMONX CHARTIS TABLET CONSOLE $1,067 15 payments
  10. ZEPHYR DELIVERY CATHETER $1,067 15 payments
  11. Other $5,889 52 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Internal Medicine: 777

Drug cost

$395

Median for Internal Medicine: $73,373

Branded share of claims

100%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Albuterol Sulfate Hfa Albuterol Sulfate Brand 12 $395

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$90,864

Medicare's payments for the services billed

Medicare patients

337

Average age 72

Services billed

1,173

182 women, 155 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 50%
Arthritis 50%
COPD 46%
Diabetes 39%
Ischemic heart disease 39%
Heart failure 36%
Depression 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

142 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record